Exact Therapeutics AS (EXTX) - Total Liabilities
Based on the latest financial reports, Exact Therapeutics AS (EXTX) has total liabilities worth Nkr37.65 Million NOK (≈ $3.96 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Exact Therapeutics AS to track the company's year-over-year net asset growth rate.
Exact Therapeutics AS - Total Liabilities Trend (2017–2024)
This chart illustrates how Exact Therapeutics AS's total liabilities have evolved over time, based on quarterly financial data.
Exact Therapeutics AS Competitors by Total Liabilities
The table below lists competitors of Exact Therapeutics AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bluelinea SA
PA:ALBLU
|
France | €8.79 Million |
|
Golden Sky Minerals Corp
V:AUEN
|
Canada | CA$1.01 Million |
|
2cureX AB
ST:2CUREX
|
Sweden | Skr4.55 Million |
|
AquaBounty Technologies Inc
NASDAQ:AQB
|
USA | $12.38 Million |
|
Kanger International Bhd
KLSE:0170
|
Malaysia | RM36.56 Million |
|
Interbud-Lublin SA
WAR:ITB
|
Poland | zł52.17 Million |
|
Austin Metals Ltd
AU:AYT
|
Australia | AU$201.35K |
Liability Composition Analysis (2017–2024)
This chart breaks down Exact Therapeutics AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Exact Therapeutics AS (EXTX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.65 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Exact Therapeutics AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Exact Therapeutics AS (2017–2024)
The table below shows the annual total liabilities of Exact Therapeutics AS from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr37.65 Million ≈ $3.96 Million |
+132.15% |
| 2023-12-31 | Nkr16.22 Million ≈ $1.71 Million |
-6.79% |
| 2022-12-31 | Nkr17.40 Million ≈ $1.83 Million |
+46.38% |
| 2021-12-31 | Nkr11.89 Million ≈ $1.25 Million |
+12.36% |
| 2020-12-31 | Nkr10.58 Million ≈ $1.11 Million |
+7.21% |
| 2019-12-31 | Nkr9.87 Million ≈ $1.04 Million |
+59.89% |
| 2018-12-31 | Nkr6.17 Million ≈ $649.40K |
-47.15% |
| 2017-12-31 | Nkr11.68 Million ≈ $1.23 Million |
-- |
About Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more